Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Golimumab Response Prediction in Ulcerative Colitis
NCT01988961Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2013
- Primary completion
- Feb 2015
- Modality
- Monoclonal Antibodies
- Countries
- 12
01
Overview
Phase 2, open-label, single-arm trial of golimumab in ulcerative colitis (UC), sponsored by Janssen Pharmaceutical. Primary endpoint: Area under the Receiver Operating Characteristic curve of a subset of the length-109 probe set panel as a predictor of mucosal healing at Week 6. Started Dec 2013; status: completed.
02
Drugs
golimumab
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT01988961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01988961.